Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease

J. L. Holley, T. A. Nolan, B. Piraino

Research output: Contribution to journalArticlepeer-review

Abstract

Recombinant human erythropoietin (rHuEpo) is an established, effective treatment for the anemia of chronic renal failure. Recent reports also suggest it may be efficacious in the anemias of drug toxicity, rheumatoid arthritis, and multiple myeloma without renal failure. We describe the positive response to rHuEpo in an end-state renal disease patient with active multiple myeloma and ongoing chemotherapy. Before rHuEpo therapy, the patient was transfusion dependent, but after rHuEpo was initiated, transfusions were not required. Multiple myeloma with renal failure does not preclude a response to rHuEpo. Further trials of rHuEpo in the treatment of multiple myeloma with and without renal failure are warranted.

Original languageEnglish (US)
Pages (from-to)145-147
Number of pages3
JournalClinical Nephrology
Volume37
Issue number3
StatePublished - Jan 1 1992
Externally publishedYes

Keywords

  • Dialysis
  • Erythropoietin
  • Multiple myeloma

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease'. Together they form a unique fingerprint.

Cite this